Healixa Inc. announces that Christopher Galliano will join its Board of Directors as a non-executive independent Director effective January 11, 2022, demonstrating the company's focus on corporate governance, growth and national list requirements. Mr. Galliano currently serves as Chief Technology Officer and Co-Founder of Skymount Medical, where he co-authored over 6 patents in artificial intelligence based drug discovery and leads the day to day research to construct an oral therapeutic for COVID-19 and 12 other active inventions/pharmaceutical developments.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.129 USD | +3.32% | +29.00% | -53.93% |
1st Jan change | Capi. | |
---|---|---|
-53.93% | 9.19Cr | |
+10.02% | 3,07500Cr | |
+8.25% | 8.5TCr | |
+4.44% | 7.74TCr | |
-14.07% | 5.39TCr | |
-23.14% | 4.76TCr | |
+21.96% | 4.66TCr | |
+21.64% | 4.28TCr | |
+59.16% | 3.7TCr | |
-10.56% | 2.46TCr |
- Stock Market
- Equities
- EMOR Stock
- News Healixa Inc.
- Healixa, Inc. Appoints Christopher Galliano as Independent Director to its Board